ProCE Banner Activity

Key Updates in the Treatment of Hormone Receptor–Positive Breast Cancer

Clinical Thought
Experts discuss key updates in hormone receptor–positive breast cancer, including recent data presented at ASCO 2022.

Released: July 18, 2022

Expiration: July 17, 2023

No longer available for credit.

Share

Faculty

Komal Jhaveri

Komal Jhaveri, MD, FACP

Associate Attending
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

Erica Mayer

Erica Mayer, MD, MPH

Director of Breast Cancer Clinical Research
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Laura M. Spring

Laura M. Spring, MD

Breast Medical Oncologist
Mass General Cancer Center
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Lilly

Novartis Pharmaceuticals Corporation

Sanofi Genzyme

Program Director Disclosure

Program Director

Komal Jhaveri, MD, FACP

Associate Attending
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

Komal Jhaveri, MD, FACP: consultant: AbbVie, AstraZeneca, Biotheranostics, Blueprint Medicines, Bristol-Myers Squibb, Daiichi Sankyo, Eisai, Genentech, Jounce Therapeutics, Lilly, Novartis, Pfizer, Seattle Genetics, Sun Pharma, Taiho Oncology; researcher: ADC Therapeutics, AstraZeneca, Clovis Oncology, Debiopharm, Genentech, Immunomedics/Gilead, Lilly, Merck/VelosBio, Novartis, Novita Pharmaceuticals, Pfizer, Puma, Zymeworks.

Faculty Disclosure

Primary Author

Erica Mayer, MD, MPH

Director of Breast Cancer Clinical Research
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Erica L. Mayer, MD, MPH: consultant: AstraZeneca, Gilead Sciences, Lilly, Novartis.

Laura M. Spring, MD

Breast Medical Oncologist
Mass General Cancer Center
Harvard Medical School
Boston, Massachusetts

Laura M. Spring, MD: consultant: Novartis, Puma; researcher: Merck, Phillips.